scholarly journals Chemosensory Dysfunction, Oral Disorders and Oral Health-Related Quality Of Life in Patients with Primary Sjögren's Syndrome: Comparative Cross-Sectional Study

2020 ◽  
Author(s):  
Mirjana Šijan Gobeljić ◽  
Vera Milić ◽  
Nada Pejnovic ◽  
Nemanja Damjanov
Keyword(s):  
Oral Health ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Healthy Controls ◽  
Primary Sjogren’S Syndrome ◽  
Age And Gender ◽  
Primary Sjögren's Syndrome ◽  
And Gender ◽  
Sjögren‘S Syndrome

Abstract Background: The aim of this study was to evaluate chemosensory function and oral disorders in patients with primary Sjögren's syndrome (pSS) and to compare these findings with those of age- and gender-matched healthy controls. Methods: Olfactory and gustatory function, dysgeusia, burning sensations in the tongue (BST), halitosis, and oral health-related quality of life (OHRQoL) using the short-form Oral Health Impact Profile (OHIP-14) were evaluated in 58 patients with primary Sjögren’s syndrome (pSS) and 55 age- and gender-matched healthy controls in this comparative cross-sectional study. Results: Patients with pSS had significantly lower self-reported visual analogue scale (VAS) smell score (8.6±2.2 vs. 9.6±0.7, p=0.016) and VAS taste score (9.5±0.7 vs. 8.5±2.1, p=0.014) than healthy controls. A greater proportion of patients with pSS had anosmia (3.8% vs. 0.0%) or hyposmia (36.5% vs. 13.2%) and ageusia for basic tastes: sweetness (34.0% vs. 7.5%), sourness (10.6 % vs. 0.0), saltiness (10.0% vs. 5.7%) or bitterness (19.1% vs. 1.9%) as evaluated using Sniffin Sticks test and taste stripts, respectively. A higher proportion of pSS patients complained of dysgeusia (52.6% vs. 9.4%, p<0.0001) and BST (45.6% vs. 0.0%, p<0.0001) while similar number of pSS patients and controls reported halitosis (31.6% vs. 28.3%, p=0.434). The mean OHIP-14 score was significantly higher in patients with pSS (6.8±7.0 vs. 2.3±8.5, p<0.001) indicating patients’ poorer OHRQoL compared to controls. Conclusions: The majority of patients with pSS had impaired chemosensory function and indicators of oral health in comparison to the age- and gender-matched healthy controls. Further studies of oral hygiene habits and dietary intake of these patients are needed to ensure better management of oral health problems in patients with pSS.

scholarly journals Chemosensory Dysfunction and Oral Disorders Affect Oral Health-Related Quality Of Life in Patients with Primary Sjögren's Syndrome

2020 ◽  
Author(s):  
Mirjana Šijan Gobeljić ◽  
Vera Milić ◽  
Nada Pejnovic ◽  
Nemanja Damjanov
Keyword(s):  
Oral Health ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Healthy Controls ◽  
Primary Sjogren’S Syndrome ◽  
Age And Gender ◽  
Primary Sjögren's Syndrome ◽  
And Gender ◽  
Sjögren‘S Syndrome

Abstract Background: The aim of this study was to evaluate chemosensory function and oral disorders in patients with primary Sjögren's syndrome (pSS) and to compare these findings with those of age- and gender-matched healthy controls.Methods: Olfactory and gustatory function, dysgeusia, burning sensations in the tongue (BST), halitosis, and oral health-related quality of life (OHRQoL) using the short-form Oral Health Impact Profile (OHIP-14) were evaluated in 58 patients with primary Sjögren’s syndrome (pSS) and 55 age- and gender-matched healthy controls.Results: Patients with pSS had significantly lower self-reported visual analogue scale (VAS) smell score (8.6±2.2 vs. 9.6±0.7, p=0.016) and VAS taste score (9.5±0.7 vs. 8.5±2.1, p=0.014) than healthy controls. A greater proportion of patients with pSS had anosmia (3.8% vs. 0.0%) or hyposmia (36.5% vs. 13.2%) and ageusia for basic tastes: sweetness (34.0% vs. 7.5%), sourness (10.6 % vs. 0.0), saltiness (10.0% vs. 5.7%) or bitterness (19.1% vs. 1.9%). A higher proportion of pSS patients complained of dysgeusia (52.6% vs. 9.4%, p<0.0001) and BST (45.6% vs. 0.0%, p<0.0001) while similar number of pSS patients and controls reported halitosis (31.6% vs. 28.3%, p=0.434). The mean OHIP-14 score was significantly higher in patients with pSS (6.8±7.0 vs. 2.3±8.5, p<0.001) indicating patients’ poorer OHRQoL compared to controls. Conclusions: The majority of patients with pSS had impaired chemosensory function and indicators of oral health in comparison to the age- and gender-matched healthy controls. Further studies of oral hygiene habits and dietary intake of these patients are needed to ensure better management of oral health problems in patients with pSS.

scholarly journals Chemosensory Dysfunction, Oral Disorders and Oral Health-Related Quality Of Life in Patients with Primary Sjögren's Syndrome: Comparative Cross-Sectional Study

2020 ◽  
Author(s):  
Mirjana Šijan Gobeljić ◽  
Vera Milić ◽  
Nada Pejnovic ◽  
Nemanja Damjanov
Keyword(s):  
Oral Health ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Healthy Controls ◽  
Primary Sjogren’S Syndrome ◽  
Age And Gender ◽  
Primary Sjögren's Syndrome ◽  
And Gender ◽  
Sjögren‘S Syndrome

Abstract Background: The aim of this study was to evaluate chemosensory function and oral disorders in patients with primary Sjögren's syndrome (pSS) and to compare these findings with those of age- and gender-matched healthy controls.Methods: This comparative cross-sectional study included 58 patients with primary Sjögren’s syndrome (pSS) and 55 age- and gender-matched healthy controls. Olfactory and gustatory function, burning sensations in the tongue (BST) and halitosis were assessed. Oral health-related quality of life (OHRQoL) was evaluated using the short-form Oral Health Impact Profile (OHIP-14).Results: Patients with pSS had significantly lower self-reported visual analogue scale (VAS) smell score (8.6±2.2 vs. 9.6±0.7, p=0.016) and VAS taste score (9.5±0.7 vs. 8.5±2.1, p=0.014) than healthy controls. A greater proportion of patients with pSS had anosmia (3.8% vs. 0.0%) or hyposmia (36.5% vs. 13.2%) and ageusia for basic tastes: sweetness (34.0% vs. 7.5%), sourness (10.6 % vs. 0.0), saltiness (10.0% vs. 5.7%) or bitterness (19.1% vs. 1.9%) as evaluated using Sniffin Sticks test and taste stripts, respectively. A higher proportion of pSS patients complained of dysgeusia (52.6% vs. 9.4%, p<0.0001) and BST (45.6% vs. 0.0%, p<0.0001), while similar number of patients with pSS and controls reported halitosis (31.6% vs. 28.3%, p=0.434). The mean OHIP-14 score was significantly higher in patients with pSS (6.8±7.0 vs. 2.3±8.5, p<0.001) indicating patients’ poorer OHRQoL compared with controls. Conclusions: The majority of patients with pSS had impaired chemosensory function and indicators of oral health in comparison with the age- and gender-matched healthy controls. Further studies of oral hygiene habits and dietary intake of these patients are needed to ensure better management of oral health problems in patients with pSS.

scholarly journals HIF1A(rs11549465) andAKNA(rs10817595) Gene Polymorphisms Are Associated with Primary Sjögren’s Syndrome

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Gabriela Hernández-Molina ◽  
José Manuel Rodríguez-Pérez ◽  
Javier Fernández-Torres ◽  
Guadalupe Lima ◽  
Nonanzit Pérez-Hernández ◽  
...  
Keyword(s):  
Gene Polymorphisms ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Age And Gender ◽  
Primary Sjögren's Syndrome ◽  
And Gender ◽  
Sjögren‘S Syndrome

Objective. To evaluate the allele and genotype frequencies of polymorphic sites ofHIF1AandANKAgenes in primary Sjögren’s syndrome (pSS).Methods. We included 110 patients with pSS and 141 ethnically matched healthy controls. ThreeHIF1Agene polymorphisms(Pro582Ser,Ala588Thr, andC191T)and twoAKNA genepolymorphisms(−1372C>AandPro624Leu)were genotyped using TaqMan probes in a Real-Time PCR instrument. Associations between pSS and genotypes, alleles, and inheritance models of the SNPs of interest were evaluated by logistic regression adjusted by age and gender.Results. TheC/Tgenotype and theTallele of theHIF1A Pro582Serpolymorphism protected against pSS (OR = 0.22; 95% CI = 0.09–0.52;P<0.01; OR = 0.26; 95% CI = 0.12–0.58;P<0.01, resp.), whereas under a recessive model adjusted by age and gender, theAKNA −1372C>Apolymorphism A/A genotype was associated with an increased risk of pSS (OR = 2.60; 95% CI = 1.11–6.12;P=0.03).Conclusions. We identifiedHIF1A Pro582SerTallele andC/Tgenotype as well asAKNA −1372C>Apolymorphism A/A genotype as genetic factors associated with pSS. Further studies in other populations are needed to validate our findings and research is warranted in order to shed some light on their functional implications across biological pathways in this disease.

scholarly journals The Imbalance of Circulating Follicular T Helper Cell Subsets in Primary Sjögren’s Syndrome Associates With Serological Alterations and Abnormal B-Cell Distribution

2021 ◽  
Vol 12 ◽  
Author(s):  
Krisztina Szabó ◽  
Ilona Jámbor ◽  
Antónia Szántó ◽  
Ildikó Fanny Horváth ◽  
Tünde Tarr ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Healthy Controls ◽  
T Helper ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

Since B-cell hyperactivity and pathologic antibody response are key features in the immunopathogenesis of primary Sjögren’s syndrome (pSS), the role of follicular T helper (TFH) cells as efficient helpers in the survival and differentiation of B cells has emerged. Our aim was to investigate whether a change in the balance of circulating (c)TFH subsets and follicular regulatory T (TFR) cells could affect the distribution of B cells in pSS. Peripheral blood of 38 pSS patients and 27 healthy controls was assessed for the frequencies of cTFH cell subsets, TFR cells, and certain B cell subpopulations by multicolor flow cytometry. Serological parameters, including anti-SSA, anti-SSB autoantibodies, immunoglobulin, and immune complex titers were determined as part of the routine diagnostic evaluation. Patients with pSS showed a significant increase in activated cTFH cell proportions, which was associated with serological results. Frequencies of cTFH subsets were unchanged in pSS patients compared to healthy controls. The percentages and number of cTFR cells exhibited a significant increase in autoantibody positive patients compared to patients with seronegative pSS. The proportions of transitional and naïve B cells were significantly increased, whereas subsets of memory B cells were significantly decreased and correlated with autoantibody production. Functional analysis revealed that the simultaneous blockade of cTFH and B cell interaction with anti-IL-21 and anti-CD40 antibodies decreased the production of IgM and IgG. Imbalance in TFH subsets and TFR cells indicates an ongoing over-activated humoral immune response, which contributes to the characteristic serological manifestations and the pathogenesis of pSS.

scholarly journals Adropin Serum Levels in Patients with Primary Sjögren’s Syndrome

Biomolecules ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1296
Author(s):  
Marijana Janković Danolić ◽  
Dijana Perković ◽  
Marin Petrić ◽  
Igor Barišić ◽  
Katarina Gugo ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Control Group ◽  
Healthy Controls ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

Primary Sjögren’s syndrome (pSS) patients have higher prevalence of endothelial dysfunction and premature atherosclerosis. Recent studies investigated adropin, a secretory protein that can regulate lipid metabolism and insulin resistance and protect endothelial cells’ function and that has an anti-inflammatory effect. The aim of this study was to determine adropin levels in pSS patients compared to healthy controls. Additional goals were exploring the correlation between adropin and several metabolic and immunological parameters in pSS, including disease specific antibodies, EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), and Sjögren’s Syndrome Disease Damage Index (SSDDI). This research included 52 pSS patients and 52 healthy controls. pSS patients have significantly higher adropin levels compared to the control group (3.76 ± 0.68 vs. 3.14 ± 0.69 ng/mL, p < 0.001). Correlation analysis showed that adropin levels in pSS patients have positive correlation with high-density lipoprotein (HDL) (r = 0.290, p = 0.036) and anti SSA/Ro52 antibodies (r = 0.307, p = 0.026) and negative correlation with SSDDI (r = −0.401, p = 0.003). Multivariant linear regression showed that adropin levels are independently associated with HDL (β ± SE, 0.903 ± 0.283, p = 0.002) and SSDDI (β ± SE, −0.202 ± 0.073, p = 0.008). Our findings imply that adropin could be involved in the pathophysiology of pSS, yet it remains to be elucidated in future studies whether adropin has a protective or detrimental role in this setting.

scholarly journals Connection between the Gut Microbiome, Systemic Inflammation, Gut Permeability and FOXP3 Expression in Patients with Primary Sjögren’s Syndrome

2020 ◽  
Vol 21 (22) ◽  
pp. 8733
Author(s):  
Antonio Cano-Ortiz ◽  
Aurora Laborda-Illanes ◽  
Isaac Plaza-Andrades ◽  
Alberto Membrillo del Pozo ◽  
Alberto Villarrubia Cuadrado ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Healthy Controls ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

The aims of this study were to explore intestinal microbial composition and functionality in primary Sjögren’s syndrome (pSS) and to relate these findings to inflammation, permeability and the transcription factor Forkhead box protein P3 (FOXP3) gene expression in peripheral blood. The study included 19 pSS patients and 19 healthy controls matched for age, sex, and body mass index. Fecal bacterial DNA was extracted and analyzed by 16S rRNA sequencing using an Ion S5 platform followed by a bioinformatics analysis using Quantitative Insights into Microbial Ecology (QIIME II) and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). Our data suggest that the gut microbiota of pSS patients differs at both the taxonomic and functional levels with respect to healthy controls. The gut microbiota profile of our pSS patients was characterized by a lower diversity and richness and with Bacteroidetes dominating at the phylum level. The pSS patients had less beneficial or commensal butyrate-producing bacteria and a higher proportion of opportunistic pathogens with proinflammatory activity, which may impair intestinal barrier function and therefore contribute to inflammatory processes associated with pSS by increasing the production of proinflammatory cytokines and decreasing the release of the anti-inflammatory cytokine IL-10 and the peripheral FOXP3 mRNA expression, implicated in the development and function of regulatory T cells (Treg) cells. Further studies are needed to better understand the real impact of dysbiosis on the course of pSS and to conceive preventive or therapeutic strategies to counteract microbiome-driven inflammation.

scholarly journals AB1235 SALIVARY LEVEL OF CALPROTECTIN (MRP 8/14) AS A BIOMARKER FOR SJÖGREN SYNDROME – A PROSPECTIVE OBSERVATIONAL STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1908.3-1908
Author(s):  
P. Chebbi ◽  
J. Kabeer ◽  
P. Sandhya ◽  
M. Gowri ◽  
D. Danda
Keyword(s):  
Healthy Subjects ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Healthy Controls ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Oral Symptoms ◽  
Sjögren‘S Syndrome

Background:Objectives:Calprotectin (MRP 8/14) is secreted by neutrophils and monocytes in an inflammatory milieu(1). Increased levels of calprotectin in blood and faeces has been previously shown in patients with primary Sjogren’s syndrome(pSS)(2). We hypothesised Calprotectin in saliva may therefore potentially reflect inflammation in salivary glands. In the present study, we aimed to assess the utility of salivary calprotectin as a biomarker in pSS and to evaluate the potential association of calprotectin with clinical features, laboratory markers and disease activity indexes in pSS.Methods:Consecutive patients attending rheumatology clinic between September 2016 and July 2017 of age more than 18 years fulfilling either American European Consensus Group (AECG) 2002 or 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome, constituted the case group. Patients with sicca non-pSS and rheumatoid arthritis patients satisfying ACR/EULAR criteria 2010 were recruited as disease controls. Age and sex-matched healthy subjects were recruited as a controls. Patient history, signs and symptoms, laboratory investigations, ESSDAI and ESSPRI scoring were noted for cases and disease controls. Unstimulated saliva was collected by the spitting method. Salivary calprotectin levels were quantified by commercially available ELISA kit(R&D Systems, MN, USA).Results:A total of 42 pSS cases (41.59 11.21 years, 40 women), 40 disease controls (47.62 9.81 years, 39 women) and 30 healthy controls (36 10.65 years, 29 women) were recruited. In pSS and disease controls, the median levels of salivary calprotectin [38.5(81) and 52(69.5 ng/ml)] were significantly higher compared to healthy controls [26.5(29) {p=0.001}]. Salivary calprotectin levels in pSS was positively associated with oral symptoms and negatively associated with immunosuppression of 1 year and more(P=0.04 and 0.03 respectively),but not ESSDAI,ESSPRI scores or lab parameters.Conclusion:Salivary calprotectin was elevated in pSS compared to healthy subjects and was found to be positively associated with oral symptoms and with immunosuppressive treatment.References:[1]Stroncek DF, Shankar RA, Skubitz KM. The subcellular distribution of myeloid-related protein 8 (MRP8) and MRP14 in human neutrophils. J Transl Med. 2005 Sep 28;3:36.[2]Fagerhol MK, Larsen A, Brun JG, Hammer HB, Angel K, Kvien TK, et al. Large molecular size EDTA-resistant complexes containing S100A12, ERAC, in serum during inflammatory conditions. Scand J Clin Lab Invest. 2012 Apr;72(2):129–36.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document